Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the FRRS1L gene.
Features include always present findings: Absent speech, Choreoathetosis, Global developmental delay, and Chorea and others; and common findings: Focal hemiclonic seizure, Reduced movement (hypokinesia), Loss of previously acquired skills (developmental regression), and Muscle stiffness (rigidity) and others. 21 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 16 | Bilateral tonic-clonic seizure, Brain shrinkage (cerebral atrophy), Focal hemiclonic seizure |
FRRS1L encodes ferric chelate reductase 1 like (293 aa). Important modulator of glutamate signaling pathway Highest expression in Brain Cerebellar Hemisphere (53.7 TPM) and Brain Cerebellum (43.9 TPM).
Developmental and epileptic encephalopathy, 37 is associated with mutations in the FRRS1L gene on chromosome 9.
FRRS1L is classified as a druggable target with score 0.0.
Genetic testing for FRRS1L is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for developmental and epileptic encephalopathy, 37 has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 6 common features.
No clinical trials have been registered for developmental and epileptic encephalopathy, 37.
74 publications have been identified in PubMed for developmental and epileptic encephalopathy, 37. Research spans Epidemiology / Natural History (41%), Review / Meta-Analysis (20%), and Clinical Trial Publication (20%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 29 | 41% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:52 PM UTC
Online Mendelian Inheritance in Man
Muscles | 3 | Brain shrinkage (cerebral atrophy), Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia) |
Eyes | 1 | Nystagmus |
Age of onset: childhood.
Research summaries |
14 |
20% |
Clinical study results | 14 | 20% |
Patient case studies | 9 | 13% |
Laboratory research | 3 | 4% |
Testing and diagnosis research | 1 | 1% |
New treatment approaches | 1 | 1% |
Diaz JA (2026). [PMID: 42181696](https://pubmed.ncbi.nlm.nih.gov/42181696/). *Mol Ther Nucleic Acids*. [Gene Therapy / Novel Therapeutics]
Sundman AK (2026). [PMID: 40986435](https://pubmed.ncbi.nlm.nih.gov/40986435/). *Brain*. [Review / Meta-Analysis]
Wang PY (2026). [PMID: 41725720](https://pubmed.ncbi.nlm.nih.gov/41725720/). *Front Neurol*. [Basic Science / Preclinical]
Lea TA (2026). [PMID: 41380247](https://pubmed.ncbi.nlm.nih.gov/41380247/). *Epilepsy Behav*. [Epidemiology / Natural History]
Swartwood SM (2026). [PMID: 42138251](https://pubmed.ncbi.nlm.nih.gov/42138251/). *Epilepsia Open*. [Epidemiology / Natural History]
Stjerna S (2026). [PMID: 41352090](https://pubmed.ncbi.nlm.nih.gov/41352090/). *Brain Dev*. [Epidemiology / Natural History]
Benítez-Provedo C (2026). [PMID: 42184160](https://pubmed.ncbi.nlm.nih.gov/42184160/). *Epilepsia*. [Case Report / Case Series]
Torbati PN (2026). [PMID: 41633218](https://pubmed.ncbi.nlm.nih.gov/41633218/). *Pediatr Neurol*. [Epidemiology / Natural History]
Kansal B (2026). [PMID: 41498396](https://pubmed.ncbi.nlm.nih.gov/41498396/). *Mov Disord Clin Pract*. [Epidemiology / Natural History]
Ślusarczyk K (2026). [PMID: 41581294](https://pubmed.ncbi.nlm.nih.gov/41581294/). *Mol Genet Metab*. [Case Report / Case Series]